Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T P Kruck

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Biochimica Et Biophysica Acta|November 2, 1987
Acetylcholine receptor density and binding in murine dystrophyT P Kruck, D M Logan
Biochemistry|October 12, 1982
Neurotoxins from Bungarus fasciatus venom: a simple fractionation and separation of alpha- and beta-type neurotoxins and their partial characterizationT P Kruck, D M Logan
Journal of Inorganic Biochemistry|February 1, 1979
A comparative study of Zn(II) and Co(II) binding to glycyl-L-tyrosine, a pseudosubstrate for carboxypeptidase AD W Appleton, T P Kruck, B Sarkar
Journal of Chromatography|May 31, 1985
Determination of desferoxamine and a major metabolite by high-performance liquid chromatography. Application to the treatment of aluminium-related disordersT P Kruck, W Kalow, D R McLachlan
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|November 1, 1989
New evidence for an active role of aluminum in Alzheimer's diseaseD R McLachlan, W J Lukiw, T P Kruck
Neurotoxicology|January 1, 1987
Alterations in human linker histone-DNA binding in the presence of aluminum salts in vitro and in Alzheimer's diseaseW J Lukiw, T P Kruck, D R McLachlan
Clinical Pharmacology and Therapeutics|October 1, 1990
Suppression of deferoxamine mesylate treatment-induced side effects by coadministration of isoniazid in a patient with Alzheimer's disease subject to aluminum removal by ionspecific chelationT P Kruck, E A Fisher, D R McLachlan
Clinical Pharmacology and Therapeutics|January 1, 1993
A predictor for side effects in patients with Alzheimer's disease treated with deferoxamine mesylateT P Kruck, E A Fisher, D R McLachlan
Therapeutic Drug Monitoring|December 1, 1993
Desferrioxamine and Alzheimer's disease: video home behavior assessment of clinical course and measures of brain aluminumD R McLachlan, W L Smith, T P Kruck
FEBS Letters|August 14, 1989
Linker histone-DNA complexes: enhanced stability in the presence of aluminum lactate and implications for Alzheimer's diseaseW J Lukiw, T P Kruck, D R McLachlan
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Biochimica Et Biophysica Acta|November 2, 1987
Acetylcholine receptor density and binding in murine dystrophyT P Kruck, D M Logan
Biochemistry|October 12, 1982
Neurotoxins from Bungarus fasciatus venom: a simple fractionation and separation of alpha- and beta-type neurotoxins and their partial characterizationT P Kruck, D M Logan
Journal of Inorganic Biochemistry|February 1, 1979
A comparative study of Zn(II) and Co(II) binding to glycyl-L-tyrosine, a pseudosubstrate for carboxypeptidase AD W Appleton, T P Kruck, B Sarkar
Journal of Chromatography|May 31, 1985
Determination of desferoxamine and a major metabolite by high-performance liquid chromatography. Application to the treatment of aluminium-related disordersT P Kruck, W Kalow, D R McLachlan
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|November 1, 1989
New evidence for an active role of aluminum in Alzheimer's diseaseD R McLachlan, W J Lukiw, T P Kruck
Neurotoxicology|January 1, 1987
Alterations in human linker histone-DNA binding in the presence of aluminum salts in vitro and in Alzheimer's diseaseW J Lukiw, T P Kruck, D R McLachlan
Clinical Pharmacology and Therapeutics|October 1, 1990
Suppression of deferoxamine mesylate treatment-induced side effects by coadministration of isoniazid in a patient with Alzheimer's disease subject to aluminum removal by ionspecific chelationT P Kruck, E A Fisher, D R McLachlan
Clinical Pharmacology and Therapeutics|January 1, 1993
A predictor for side effects in patients with Alzheimer's disease treated with deferoxamine mesylateT P Kruck, E A Fisher, D R McLachlan
Therapeutic Drug Monitoring|December 1, 1993
Desferrioxamine and Alzheimer's disease: video home behavior assessment of clinical course and measures of brain aluminumD R McLachlan, W L Smith, T P Kruck
FEBS Letters|August 14, 1989
Linker histone-DNA complexes: enhanced stability in the presence of aluminum lactate and implications for Alzheimer's diseaseW J Lukiw, T P Kruck, D R McLachlan
Pageof 2